Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $70.1K | — | — |
| Operating income | -$1.80M | -$5.93M | -$9.72M |
| Operating margin | -2563.5% | — | — |
| Net income | -$2.04M | -$5.86M | -$9.16M |
| Net margin | -2909.1% | — | — |
| EPS (diluted) | -$0.33 | -$0.89 | -$1.09 |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Operating cash flow | -$1.18M | -$8.51M | -$6.50M |
| Capital expenditures | $289K | $396K | $170K |
| Free cash flow | -$1.47M | -$8.90M | -$6.67M |
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Cash & equivalents | $66.5K | $9.72M | $3.04M |
| Total assets | $3.56M | $13.0M | $5.97M |
| Total liabilities | $3.94M | $2.61M | $2.57M |
| Shareholders' equity | -$384K | $10.4M | $3.40M |
| Retained earnings | -$6.08M | -$11.9M | -$21.1M |
| Shares (wtd avg diluted) | 6.25M | 6.56M | 8.38M |
Every figure is extracted from EXOZYMES INC.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.